| # | Drug | Count |
|---|---|---|
| 0 | NIVOLUMAB | 1527 |
| 1 | IPILIMUMAB | 1171 |
| 2 | PEMBROLIZUMAB | 1153 |
| 3 | CARBOPLATIN | 567 |
| 4 | PACLITAXEL | 341 |
| 5 | PACLITAXEL (AIBUMIN-BOUND) | 305 |
| 6 | DURVALUMAB | 238 |
| 7 | PEMETREXED DISODIUM | 230 |
| 8 | ATEZOLIZUMAB | 203 |
| 9 | CILTACABTAGENE AUTOLEUCEL | 187 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | ENSITRELVIR | 1 | 0.0556 |
| 1 | TREMELIMUMAB | 159 | 0.0359 |
| 2 | CILTACABTAGENE AUTOLEUCEL | 187 | 0.0285 |
| 3 | IPILIMUMAB | 1171 | 0.0267 |
| 4 | PENPULIMAB | 2 | 0.0204 |
| 5 | NIVOLUMAB | 1527 | 0.0156 |
| 6 | ONTRUZANT | 8 | 0.0153 |
| 7 | ZANIDATAMAB-HRII | 1 | 0.0122 |
| 8 | NALDEMEDINE | 20 | 0.0120 |
| 9 | DURVALUMAB | 238 | 0.0110 |
| # | Drug class | Count |
|---|---|---|
| 0 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 1528 |
| 1 | CTLA-4-directed Blocking Antibody [EPC] | 1330 |
| 2 | Platinum-based Drug [EPC] | 780 |
| 3 | Corticosteroid [EPC] | 369 |
| 4 | Microtubule Inhibitor [EPC] | 366 |
| 5 | Programmed Death Ligand-1 Blocker [EPC] | 238 |
| 6 | Nonsteroidal Anti-inflammatory Drug [EPC] | 190 |
| 7 | Folate Analog Metabolic Inhibitor [EPC] | 180 |
| 8 | Proton Pump Inhibitor [EPC] | 147 |
| 9 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 141 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | CTLA-4-directed Blocking Antibody [EPC] | 1330 | 0.0276 |
| 1 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 1528 | 0.0155 |
| 2 | Bispecific HER2-directed Antibody [EPC] | 1 | 0.0122 |
| 3 | Programmed Death Ligand-1 Blocker [EPC] | 238 | 0.0110 |
| 4 | Lymphocyte Growth Factor [EPC] | 7 | 0.0055 |
| 5 | Platinum-based Drug [EPC] | 780 | 0.0028 |
| 6 | Substance P/Neurokinin-1 Receptor Antagonist [EPC] | 24 | 0.0028 |
| 7 | Microtubule Inhibitor [EPC] | 366 | 0.0022 |
| 8 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 13 | 0.0021 |
| 9 | Lymphocyte Activation Gene-3 Blocker [EPC] | 1 | 0.0019 |